Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call
Sangamo Therapeutics (Nasdaq: SGMO) said it will release its fourth quarter and full year 2025 financial results after market close on Monday, March 30, 2026.
Rhea-AI Summary
Sangamo Therapeutics (Nasdaq: SGMO) said it will release its fourth quarter and full year 2025 financial results after market close on Monday, March 30, 2026. A public conference call and webcast is set for 4:30 p.m. Eastern on March 30, 2026, followed by a replay available under Events.
Participants must register to receive dial‑in numbers and a unique passcode or use a dial‑out option; the live webcast link is on the company website in Investors and Media.
Positive
- None.
Negative
- None.
Details
News Market Reaction – SGMO
On Mar 20, the first trading day after this news, SGMO closed 2.73% below the previous close.
Data tracked by StockTitan Argus for the Mar 20 session.
Key Figures
- Results period
- Q4 and full year 2025
- Upcoming earnings release coverage
- Earnings release date
- March 30, 2026
- Scheduled after market close
- Earnings call time
- 4:30 p.m. Eastern
- Start time for public conference call
Previous Earnings Reports
-
Reported Q3 2025 results and Fabry/neurology updates with detailed STAAR data.
-
Announced timing of Q3 2025 financial results release and conference call.
-
Reported Q2 2025 results with positive STAAR data and reduced net loss.
-
Scheduled Q2 2025 financial results release and earnings call details.
-
Reported Q1 2025 results with Lilly license, milestones, and equity offering.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RICHMOND, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2025 financial results after the market closes on Monday, March 30, 2026.
The company will hold a conference call at 4:30 p.m. Eastern on Monday, March 30, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates.
Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events.
A replay will be available following the conference call, accessible under Events.
About Sangamo Therapeutics
Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo’s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit www.sangamo.com and connect with us on LinkedIn.
Investor Relations and Media Inquiries
Louise Wilkie
ir@sangamo.com
media@sangamo.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.